GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AP Biosciences Inc (ROCO:6945) » Definitions » Return-on-Tangible-Equity

AP Biosciences (ROCO:6945) Return-on-Tangible-Equity : -23.10% (As of Dec. 2024)


View and export this data going back to 2023. Start your Free Trial

What is AP Biosciences Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. AP Biosciences's annualized net income for the quarter that ended in Dec. 2024 was NT$-392.95 Mil. AP Biosciences's average shareholder tangible equity for the quarter that ended in Dec. 2024 was NT$1,701.01 Mil. Therefore, AP Biosciences's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2024 was -23.10%.

The historical rank and industry rank for AP Biosciences's Return-on-Tangible-Equity or its related term are showing as below:

ROCO:6945' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -67.85   Med: -35.24   Max: 6.59
Current: -30.33

During the past 5 years, AP Biosciences's highest Return-on-Tangible-Equity was 6.59%. The lowest was -67.85%. And the median was -35.24%.

ROCO:6945's Return-on-Tangible-Equity is ranked better than
57.89% of 1261 companies
in the Biotechnology industry
Industry Median: -43.85 vs ROCO:6945: -30.33

AP Biosciences Return-on-Tangible-Equity Historical Data

The historical data trend for AP Biosciences's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AP Biosciences Return-on-Tangible-Equity Chart

AP Biosciences Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24
Return-on-Tangible-Equity
6.59 -67.85 -35.06 -36.23 -35.24

AP Biosciences Semi-Annual Data
Dec20 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24
Return-on-Tangible-Equity Get a 7-Day Free Trial -23.07 -22.69 -50.05 -35.32 -23.10

Competitive Comparison of AP Biosciences's Return-on-Tangible-Equity

For the Biotechnology subindustry, AP Biosciences's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AP Biosciences's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AP Biosciences's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where AP Biosciences's Return-on-Tangible-Equity falls into.


;
;

AP Biosciences Return-on-Tangible-Equity Calculation

AP Biosciences's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2024 )  (A: Dec. 2023 )(A: Dec. 2024 )
=-422.746/( (779.881+1619.203 )/ 2 )
=-422.746/1199.542
=-35.24 %

AP Biosciences's annualized Return-on-Tangible-Equity for the quarter that ended in Dec. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Dec. 2024 )  (Q: Jun. 2024 )(Q: Dec. 2024 )
=-392.95/( (1782.816+1619.203)/ 2 )
=-392.95/1701.0095
=-23.10 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is two times the semi-annual (Dec. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


AP Biosciences  (ROCO:6945) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


AP Biosciences Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of AP Biosciences's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


AP Biosciences Business Description

Traded in Other Exchanges
N/A
Address
No. 3, Park Street, 17th Floor, Taipei, TWN
AP Biosciences Inc is a clinical-stage bispecific antibody new drug research and development company. It has developed a series of antibody and protein lead drugs through a self-designed technology platform for unmet medical needs, focusing on Specific targets associated with diseases to deliver safe, effective and cost-effective medicines.

AP Biosciences Headlines

No Headlines